Pharmaceutical
Biotechnology
Technology

Catalent

$45.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Catalent and other stocks, options, ETFs, and crypto commission-free!

About

CATALENT, INC., also called Catalent, is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. Read More The Softgel Technologies segment focuses on the formulation, development, and manufacture of prescription and consumer health soft capsules, softgels, vegicaps and optishell capsules. The Biologics and Specialty Drug Delivery segment researches and develop biologic drug products in prefilled syringes, vials, cartridges, blow-fill-seal unit doses, and injectable formats. The Oral Drug Delivery segment offers formulates oral dosage forms. The Clinical Supply Services segment includes the packaging, labeling, storage, distribution, and inventory management of patient kits for clinical trials of drugs. It also provides clinical e-solutions and informatics, and global comparator sourcing services. The company was founded in April 2007 and is headquartered in Somerset, NJ.

Employees
10,700
Headquarters
Somerset, New Jersey
Founded
2007
Market Cap
6.59B
Price-Earnings Ratio
42.83
Dividend Yield
0.00
Average Volume
968.62K
High Today
$45.67
Low Today
$44.55
Open Price
$45.04
Volume
120.12K
52 Week High
$47.04
52 Week Low
$29.23

Collections

Pharmaceutical
Biotechnology
Technology
Health
Medical
Packaging
2014 IPO
US

News

Yahoo FinanceMay 13

Edited Transcript of CTLT earnings conference call or presentation 7-May-19 12:15pm GMT

Q3 2019 Catalent Inc Earnings Call Somerset May 13, 2019 (Thomson StreetEvents) -- Edited Transcript of Catalent Inc earnings conference call or presentation Tuesday, May 7, 2019 at 12:15:00pm GMT TEXT version of Transcript Scroll to continue with content Ad ================================================================================ Corporate Participants ================================================================================ * John R. Chiminski Catalent, Inc. - Chairman & CEO * Thoma...

8
NasdaqMay 7

Catalent (CTLT) Surpasses Q3 Earnings Estimates

Catalent (CTLT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8.89%. A quarter ago, it was expected that this maker of drug delivery technologies would pos t earnings of $0.37 per share when it actually produced earnings of $0.45, delivering a surprise of 21.62%. Over the last fo...

12
Yahoo FinanceMay 7

Catalent: Fiscal 3Q Earnings Snapshot

SOMERSET, N.J. (AP) _ Catalent Inc. (CTLT) on Tuesday reported fiscal third-quarter profit of $31.7 million. The Somerset, New Jersey-based company said it had net income of 22 cents per share. Earnings, adjusted for one-time gains and costs, were 49 cents per share. The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of 45 cents per share. The maker of drug delivery technologies posted revenue of $617.5 million in the ...

4

Earnings

$0.18
$0.34
$0.51
$0.67
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
$0.46 per share
Actual
$0.49 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.